HCmed is specializing in drug-nebulizer combination development with its proprietary mesh nebulizer platform. The leading product Deepro mesh nebulizer has successfully received several regulatory approvals, such as European CE, US FDA 510K, CFDA, Taiwan TFDA, and Brazilian Anvisa. By providing the affordable best quality mesh platform, Deepro and breath-actuated AdheResp have been successfully licensed to CSL Behring for the global development of inhaled IgG product. HCmed’s business focus is to collaborate with our pharma partners to develop drug-nebulizer combination product globally including biologics and difficult to deliver drugs. Except the in-house R&D, APSD lab, and GMP manufacturing in Taipei to support our client’s product development from pre-clinical to commercialization, HCmed also partner with Astrazeneca I-Campus in Wuxi International Life Science Innovation Park m to cooperatively expand in China's large healthcare market.